A1

Greenheart CBD has Partnered with Paradigm Sports to Sponsor three MMA Fighters

Retrieved on: 
Wednesday, January 12, 2022 - 10:54pm

DUBLIN, IRELAND, Jan 13, 2022 - (ACN Newswire) - Greenheart CBD has partnered with Paradigm Sports to sponsor three MMA fighters: Bellator fighters Jornel Lugo and James Gallagher, and UFC fighter Walker Johnny da Silva Barra Souza.

Key Points: 
  • DUBLIN, IRELAND, Jan 13, 2022 - (ACN Newswire) - Greenheart CBD has partnered with Paradigm Sports to sponsor three MMA fighters: Bellator fighters Jornel Lugo and James Gallagher, and UFC fighter Walker Johnny da Silva Barra Souza.
  • This partnership was formed when the fighters, whose interests were piqued by the company's cryptocurrency ecosystem, reached out.
  • This in turn becomes a Greenheart CBD product, which is sold through traditional currency or by utilizing the company's token, Greenheart $CBD.
  • GreenHeart CBD Ltd, an Irish company started by two childhood friends, Mark Canavan and Paul Walsh, is innovating to improve the entire CBD production process.

Advisory - Dr. pen microneedling devices are not authorized for sale and may pose health risks

Retrieved on: 
Thursday, December 16, 2021 - 10:57pm

Issue: These devices are not authorized and may pose health risks.

Key Points: 
  • Issue: These devices are not authorized and may pose health risks.
  • Health Canada assesses the devices for their safety, quality and effectiveness before issuing medical device licences to authorize their sale.
  • In addition, to date, no microneedling devices have been authorized for at-home use, where there are higher health risks associated with inappropriate use, contamination, and infection.
  • Report adverse effects or complaints involving medical devices, including the sale of unauthorized devices, to Health Canada.

Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)

Retrieved on: 
Tuesday, December 7, 2021 - 6:42pm

A Phase 2 trial of intra-articular RTX for knee OA pain has enrolled its first two patients.

Key Points: 
  • A Phase 2 trial of intra-articular RTX for knee OA pain has enrolled its first two patients.
  • SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Phase 2 clinical study of RTX for treating knee pain from osteoarthritis (OA) has begun enrollment.
  • RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.
  • SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica.

CCCFA Issues California's First Municipal Clean Energy Project Revenue Bonds Worth over $2 Billion

Retrieved on: 
Monday, December 6, 2021 - 4:00pm

OAKLAND, Calif. andSAN RAFAEL, Calif. andSUNNYVALE, Calif., Dec. 6, 2021 /PRNewswire/ -- Three Community Choice Aggregators (CCAs) - East Bay Community Energy, MCE, and Silicon Valley Clean Energy have issued California's first ever municipal non-recourse Clean Energy Project Revenue Bonds through the California Community Choice Financing Authority (CCCFA).

Key Points: 
  • OAKLAND, Calif. andSAN RAFAEL, Calif. andSUNNYVALE, Calif., Dec. 6, 2021 /PRNewswire/ -- Three Community Choice Aggregators (CCAs) - East Bay Community Energy, MCE, and Silicon Valley Clean Energy have issued California's first ever municipal non-recourse Clean Energy Project Revenue Bonds through the California Community Choice Financing Authority (CCCFA).
  • A Clean Energy Project Revenue Bond is a form of wholesale electricity prepayment that requires three key parties: a tax-exempt public electricity supplier (the CCA), a taxable energy supplier, and a municipal bond issuer.
  • The municipal bond issuer in this case, CCCFA issues tax-exempt bonds to fund a prepayment of energy that is to be delivered over thirty years.
  • The founding members of CCCFA include Central Coast Community Energy, East Bay Community Energy, MCE, and Silicon Valley Clean Energy.

Babson College Receives Unprecedented Bond Rating Upgrades from Moody's Investors and Standard and Poor's

Retrieved on: 
Monday, November 29, 2021 - 8:30pm

WELLESLEY, Mass., Nov. 29, 2021 /PRNewswire/ --Moody's Investors and Standard and Poor's have announced significant rating upgrades for Babson College during a year of difficult pandemic challenges for institutions of higher education.

Key Points: 
  • WELLESLEY, Mass., Nov. 29, 2021 /PRNewswire/ --Moody's Investors and Standard and Poor's have announced significant rating upgrades for Babson College during a year of difficult pandemic challenges for institutions of higher education.
  • Standard and Poor's has upgraded Babson's bond rating to A+ from the prior rating of A. S&P Global Ratings assigned its 'A+' long-term rating on $51 million Series 2021 refunding revenue bonds issued by the Massachusetts Development Finance Agency on behalf of Babson College.
  • We view the management team favorably and effective in maintaining a modest tuition discount rate" (S&P 2021 rating report).
  • "The Babson community has worked together over many years to achieve these rating upgrades," said Katherine Craven, Chief Administrative Officer at Babson College.

Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer

Retrieved on: 
Monday, November 29, 2021 - 2:00pm

Based on the strength of this data, Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc., plans to advance PNV2 as the lead compound for its cancer program.

Key Points: 
  • Based on the strength of this data, Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc., plans to advance PNV2 as the lead compound for its cancer program.
  • PNV2 was tested in a metastatic breast cancer model with the primary endpoint being the amount of cancer metastases into the lungs after 28 days following orthotopic implantation of breast cancer.
  • Luciferase-engineered triple-negative breast cancer (TNBC) cells MDA-MB-231 were implanted in the mammary fat pad in female mice.
  • We are especially encouraged by this latest data in triple negative breast cancer following the recent pain data.

Alpha Lithium Secures US$30 million Investment from Uranium One with Right to Invest Additional US$185 million at Tolillar Salar, Argentina

Retrieved on: 
Monday, November 29, 2021 - 12:30pm

Alpha has formed a wholly owned subsidiary, Alpha One Lithium B.V. (Alpha One), which will be the sole owner of Alpha Lithium Argentina S.A., which in turn, will own only the Tolillar assets.

Key Points: 
  • Alpha has formed a wholly owned subsidiary, Alpha One Lithium B.V. (Alpha One), which will be the sole owner of Alpha Lithium Argentina S.A., which in turn, will own only the Tolillar assets.
  • Alpha will retain full control of Tolillar, management, and the board, and will be responsible for deploying the invested capital.
  • Upon completion of the Feasibility Study, U1 will have the option to acquire an additional 35% of Alpha One for US$185 million.
  • The Additional Consideration would be payable directly to the Company, which would imply a total value of US$743 million for the Tolillar asset.

Black Friday Beats Studio 3 Deals (2021): Early Beats Studio 3 Wireless Savings Rated by Save Bubble

Retrieved on: 
Friday, November 19, 2021 - 6:25pm

Check out Walmarts Black Friday sale and Amazons Black Friday page to enjoy more live discounts right now.

Key Points: 
  • Check out Walmarts Black Friday sale and Amazons Black Friday page to enjoy more live discounts right now.
  • Save Bubble earns commissions from purchases made using the links provided.
  • With its Pure Adaptive Noise Canceling (Pure ANC) technology, the Beats Studio 3 wireless headphones filter out external noise and further improves audio quality with real-time calibration.
  • About Save Bubble: Save Bubble round-up the latest online sales news.

Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B

Retrieved on: 
Friday, November 12, 2021 - 12:05pm

Details for the virtual e-poster are as follows:

Key Points: 
  • Details for the virtual e-poster are as follows:
    Title: First-in-Human Phase 1 Trial of SRK-181: A Latent TGF1 inhibitor, Alone or in Combination with Anti-PD-(L)1 Treatment in Patients with Advanced Solid Tumors (DRAGON trial) (#532).
  • Time: Virtual e-posters will be on display on the SITC 2021 virtual meeting platform starting November 12, 2021.
  • Highlights from the DRAGON Part A data presented at SITC include:
    As of September 7, 2021, 29 patients have been dosed in Part A of the trial.
  • The DRAGON Phase 1 proof-of-concept clinical trial (NCT04291079) in patients with locally advanced or metastatic solid tumors is ongoing.

Navidea Biopharmaceuticals Reports Third Quarter 2021 Financial Results

Retrieved on: 
Wednesday, November 10, 2021 - 9:01pm

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter and year-to-date for the period ended September 30, 2021.

Key Points: 
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter and year-to-date for the period ended September 30, 2021.
  • Total net revenues for the third quarter of 2021 were $96,000, compared to $268,000 for the same period in 2020.
  • R&D expenses for the third quarter of 2021 were $1.0 million, compared to $1.4 million in the same period in 2020.
  • Navidea ended the third quarter of 2021 with $7.2 million in cash and cash equivalents.